Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256762 · ClinicalTrials.gov registry record · Phase 2
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Phase 2 study of Locally Recurrent or Metastatic Breast Cancer, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 20
- Study locations
NCT01256762: Completed Phase 2 study of Locally Recurrent or Metastatic Breast Cancer, sponsored by Geron Corporation.
NCT01256762 is a Phase 2 study of Locally Recurrent or Metastatic Breast Cancer that has completed, run by Geron Corporation. The registered enrollment target is 166 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01256762, a Phase 2 study of Locally Recurrent or Metastatic Breast Cancer, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Primary Outcome
Defined as the time from randomization to documented disease progression, as determined by the investigator's assessment according to RECIST, or death from any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Imetelstat sodium
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- Southbay Oncology Hematology Partners - Campbell
- Cancer Care Associates - Fresno
- Memorial Miller Hospital - Long Beach
- St. Joseph Hospital - Orange
- Desert Regional Comprehensive Cancer Center - Palm Springs
- UC San Diego - San Diego
- Redwood Regional Medical Group - Santa Rosa
Georgia
- Northeast Georgia Cancer Care - Athens
- Peachtree Hematology Oncology - Atlanta
- Emory University - Atlanta
- Northeast Georgia Medical Center - Gainesville
- Central Georgia Cancer Care - Macon
Florida
- Florida Oncology Associates - Jacksonville
- Hematology Oncology Associates - Port Saint Lucie
- H. Lee Moffitt Cancer Center - Tampa
Connecticut
- Connecticut Oncology & Hematology - Torrington
- Medical Oncology Hematology - Waterbury
Alabama
- Clearview Cancer Center - Huntsville
Colorado
- Univ. Colorado at Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01256762 record still lists
NCT01256762 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Locally Recurrent or Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01256762 names 20 study sites across 6 states, led by California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT01256762 about?
NCT01256762 is a clinical study titled "Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer". The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have re...
What is the current status of trial NCT01256762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2010-11. Estimated completion is 2012-12.
What conditions does trial NCT01256762 study?
This clinical trial studies the following conditions: Locally Recurrent or Metastatic Breast Cancer.
What interventions are being tested in trial NCT01256762?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT01256762?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01256762 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01256762's enrollment target sits among peer trials
166 406th of 2000 higher than 1,591 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia